1. A pharmacist is studying the pharmacokinetics of a new anti-COVID drug and learned that the half-life of the said dru

[answerhappygod]

1. A pharmacist is studying the pharmacokinetics of a new
anti-COVID drug and learned that the half-life of the said drug is
10 hours. Which of the following can be concluded based on this
experiment?
It will take 10 hours for 50%
of the drug to diffuse through the tissues and take its
effect.
The pharmacologic effect of
the drug will last for 10 hours, after which there will be no
appreciable effect.
The drug will bind to its
receptors after 10 hours of circulating in the plasma
compartment.
It will take 10 hours for
that drug to attain 50% of its steady state.
2. An 80-year-old man who suffered from an acute stroke or
blood clot which developed in the arteries of the brain was rushed
to the emergency room. He was administered a thrombolytic drug in
an attempt to dissolve the blood clot. The physician ordered the
drug Alteplase solution, 6 mg of an intravenous loading dose
followed by an intravenous infusion. Which of the following is
incorrect regarding loading doses?
Loading doses are used for
drugs with long half-lives
The purpose of the loading
dose is to promptly raise drug concentration in the plasma.
The volume of distribution is
an important factor in loading dose.
The steady-state
concentration of the drug depends only on clearance.
3. A 72-year-old patient is administered intravenous (IV)
antibiotics with a total daily dose of 500 mg for pneumonia. The
patient improves and no longer needs to be in the hospital. She was
prescribed an oral version of the antibiotic to continue taking at
home. In comparison to the IV antibiotic, which pharmacologic
factor would be observed to have a lower value when an oral
antibiotic at the same dose is given?
The amount of drug available
prior to administration
The rate of drug elimination
from the plasma
The amount of drug absorbed
into the small intestine
The fraction of the initial
dose of a drug that reaches the systemic circulation in its active
form
4. Innovator drugs are required to conduct bioequivalence
studies.
True
False